1. Mihaylova NA. Features of clinical trials of immunomodulatory drugs of bacterial origin. In: Guidelines for clinical trials of drugs (immunobiological drugs). Part II. Moscow: Grif i K. 2012:196—9. (In Russian).
2. On the state sanitary and epidemiological welfare of the population in the Russian Federation in 2012. State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare. 2013. (In Russian).
3. Korotkaja NA, Mishinov SV, Stupak VV, Tyrinova TV, Leplina OJu, Ostanin AA, Chernyh ER. Combined immunotherapy in the treatment of glial brain tumors. Modern problems of science and education. 2017;6. (In Russian).
4. Polevshhikov AV, Rjazancev SV. Advantages of local immunotherapy in the treatment and prevention of rhinopharyngitis. The attending physician. 2002;7—8:68—70. (In Russian).
5. Nemirovskaya TI, Kovtun VP, Abramtseva MV, Alexandrova NV, Tarasov AP, Salakhova RD, Volkov VA, Merkulov VA. Immunomodulators of bacterial origin registered in the Russian Federation. Biopreparation (Biopharmaceuticals). 2014;3:19—26. (In Russian).